Dr Durayd Alzoubaidi
BMedSci, MBBS, MRCP, MD (Res)
Consultant Gastroenterologist and GI Endoscopist
Dr Durayd Alzoubaidi has expertise in gastroenterology and endoscopy and trained at Barts and the London school of medicine and completed his gastroenterology training in Cambridge and London. Mr Alzoubaidi has completed a prestigious three year post graduate research degree at University College London (UCL), studying new innovations in endoscopic therapy for gastrointestinal bleeding and cancer and has a special interest and expertise in the management and treatment of patients with acid reflux, dyspepsia, abdominal pain and barrett’s oesophagus.
He also sees patients with diarrhoea, constipation, weight loss, iron deficiency anaemia (IDA) irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
His current research involvements include the international hemospray registry analysing novel haemostatic modality in the management of gastrointestinal bleeding. He has personally presented outcomes from this research in several major international conferences and has resulted in multiple publications in peer reviewed medical journals. In addition, he is currently working on the development of a risk stratification modality to identify patients at high risk of developing cancer in the upper gastrointestinal tract.
Royal Free Hospital, Hadley Wood Hospital
Country of qualification
English, Arabic and Farsi
- Gastroenterology and Endoscopy
- General Internal Medicine
- GMC, RCP, JAG
- Flexible sigmoidoscopy
- Acid reflux
- Difficulty swallowing (dysphagia)
- Abdominal pain (less than one year)
- Barrett’s oesophagus
- Iron deficiency anaemia (IDA)
- Irritable bowel syndrome (IBS)
- Inflammatory bowel disease (IBD): crohn's disease and colitis
- Endoscopy: gastroscopy, colonoscopy and polypectomy and flexible sigmoidoscopy
Analysis of novel haemostatic modality in the management of gastrointestinal bleeding including hemospray. Currently working on the development of a risk stratification modality to identify patients at high risk of developing cancer in the upper gastrointestinal tract.